Octapharma GmbH
Pharmaceutical Companies · Mettmann
Octapharma GmbH is the German subsidiary of schweizerischen Plasmaprotein-Herstellers Octapharma AG, based in Mettmann.
Content in German
The detailed company information on this page is provided in the original German language. You can use your browser's built-in translation feature to view it in English.
Right-click on the page and select "Translate to English" or use the translation icon in your browser's address bar.
Octapharma GmbH Address & Contact
Company profile
1983
Founded
12.000+ (global)
Employees
Octapharma GmbH Overview
Octapharma GmbH is the German subsidiary of the Swiss plasma derivatives company Octapharma AG, one of the three global leaders in the manufacture of drugs derived from human blood plasma. The subsidiary is based in Mettmann, North Rhine-Westphalia, and plays a central role in the regional provision of life-saving therapies. Since its founding in 1983, Octapharma has developed into a pioneer in plasma research and processing and sets standards in the development of innovative medicines.
Plasma Derivatives: Coagulation Factors and Immunoglobulins
Octapharma's product range includes numerous essential therapies, particularly immunoglobulins such as Octagam and Nabi-HB, which are used for the treatment of immunological disorders and for the prevention of hepatitis B. Furthermore, Octapharma produces specialized coagulation factors for patients with hemophilia and Von Willebrand syndrome, including Wilate and Nuwiq. These products are crucial for the treatment of blood coagulation disorders, enabling patients to live an almost normal life.
The company also produces albumin and fibrinogen concentrates, which are supported in various medical applications, from surgery to trauma care. While many companies in the pharmaceutical industry rely on recombinant technologies, Octapharma remains committed to natural plasma-based therapies, which guarantees a strong focus on quality and patient safety.
Regulatory Classification and Quality Standards
Octapharma is subject to strict regulatory requirements governing the manufacture of medicines from human plasma. The products are approved and monitored according to the guidelines of the European Medicines Agency (EMA) and health authorities in Germany, such as the Paul-Ehrlich-Institut (PEI). This not only ensures quality standards but also the efficacy and safety of the products for patients. All plasma sources are checked according to the highest international standards to ensure flawless quality of the raw materials.
Location Mettmann
From Mettmann, Octapharma Germany coordinates the comprehensive supply for hemophilia centers, immunological practices, and hospital pharmacies. The strategic location near Düsseldorf and other medical centers in the Rhineland allows for easy access to important blood treatment centers in North Rhine-Westphalia. In line with its regional significance, Octapharma regularly conducts training and information events for medical professionals to ensure that the latest advances and therapies are available to patients.
Research and Development
Another essential aspect of Octapharma's commitment is research and development. The company continuously invests in innovative projects aimed at developing new therapeutic approaches and product variations. The focus is on improving the treatment and quality of life for patients with rare and chronic diseases. This promotion of innovations can open new therapeutic possibilities for patients with hemophilia, immune disorders, and other serious health conditions.
Social Responsibility and Donor Recruitment
Octapharma places great importance on social responsibility and community support. The company actively promotes awareness of plasma donations and operates several donation centers that allow people to donate plasma. These initiatives are central to Octapharma as they can sustainably improve the quality of life for patients. By promoting plasma donations, the company also contributes to ensuring adequate plasma donations, which are essential for the production of the necessary medicines.
More pharmaceutical companies in Germany | pharmaceutical companies in Mettmann | pharmaceutical companies in NRW
Frequently asked questions about Octapharma GmbH
What does Octapharma GmbH do?
Octapharma GmbH hat als Hauptongabe the Fraktionieren of Blut, um with den einzelnen Teilen Medikamente zu entwickeln. Diese kommen at patients with Blutstörungen zum Einsatz, are zur Unterstützung des Immunsystems eingesetzt or in the Intensivmedizin zur Verhintheung eines Schocks.
More Pharmaceutical Companies in Mettmann
Pharmaceutical Companies in Germany
Related areas in healthcare
Pharmaceutical Companies by location
About Pharmaceutical Companies
Germany is one of the world's leading pharmaceutical nations, home to more than 1,000 pharmaceutical businesses employing approximately 130,000 people (vfa 2023). Companies operating in this sector develop, manufacture and distribute medicines across the entire value chain, from early-stage research and clinical trials through to market authorisation and commercial distribution. In Germany, every manufacturer of medicinal products must hold a manufacturing authorisation (Herstellungserlaubnis) issued under Section 13 of the AMG (Arzneimittelgesetz, Germany's Medicinal Products Act). Medicines may only be placed on the market after receiving approval from either BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte, Germany's Federal Institute for Drugs and Medical Devices, broadly comparable to the FDA in the United States or the MHRA in the United Kingdom) or the European Medicines Agency (EMA) via the centralised procedure. All manufacturing sites are subject to regular GMP (Good Manufacturing Practice) inspections carried out by the competent pharmaceutical supervisory authority of the relevant German federal state. The sector covers prescription-only medicines (Rx), non-prescription OTC products, generics, biosimilars and active pharmaceutical ingredients (APIs). This directory lists pharmaceutical manufacturers, marketers and licence holders across all German federal states with full contact details, addresses and phone numbers.
Germany's Pharmaceutical Industry
Germany is consistently ranked among the top five pharmaceutical markets worldwide, generating annual revenues exceeding EUR 50 billion and accounting for the largest share of pharmaceutical production in continental Europe. The industry is represented by two major associations: vfa (Verband Forschender Arzneimittelhersteller), which represents research-based companies, and BAH (Bundesverband der Arzneimittel-Hersteller), which represents the broader manufacturer base including OTC and self-medication products. German pharmaceutical companies cover the full spectrum from global innovator corporations and mid-sized specialty manufacturers to generic producers and biotech firms. The country is a world leader in active pharmaceutical ingredient (API) production, biologics manufacturing and pharmaceutical chemistry. Key therapeutic areas of strength include oncology, cardiovascular medicine, immunology, neuroscience and rare diseases. Germany also serves as a significant export hub, with pharmaceutical products among the country's leading export categories. The sector benefits from a highly skilled workforce, world-class university research institutions and a dense network of research hospitals (Universitätsklinika) that facilitate clinical trial activity.
Regulatory Framework: BfArM, EMA and the AMG
The legal foundation for pharmaceutical activity in Germany is the Arzneimittelgesetz (AMG, German Medicinal Products Act), which regulates the authorisation, manufacture, import, distribution, labelling and pharmacovigilance of medicinal products. For English-speaking readers unfamiliar with the German regulatory landscape: BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte) is the national competent authority responsible for approving medicines marketed only in Germany, supervising narcotics, and maintaining the pharmacovigilance database. BfArM is a higher federal authority (Bundesoberbehörde) subordinate to the Federal Ministry of Health (Bundesministerium für Gesundheit). For medicines approved via the centralised EU procedure, the European Medicines Agency (EMA) grants a single marketing authorisation valid in all 27 EU member states. Germany is also home to the Paul-Ehrlich-Institut (PEI), a second federal authority that specifically handles biological medicines including vaccines, blood products and gene therapy products. Manufacturing sites are inspected by state-level pharmaceutical supervisory authorities (Landesbehörden) to verify GMP compliance, with findings entered into the EudraGMDP database operated by the EMA.
Regional Pharmaceutical Clusters in Germany
Germany's pharmaceutical industry is geographically distributed across several major regional clusters. The Rhine-Main area around Frankfurt and Leverkusen in North Rhine-Westphalia is home to some of Germany's largest pharmaceutical sites, including facilities belonging to global corporations with long histories in German chemistry and pharmaceuticals. Bavaria (particularly Munich, Penzberg and Marburg) is a second major hub, especially strong in biotechnology and biologics production. Baden-Württemberg, including cities such as Mannheim, Heidelberg and Biberach an der Riss, is home to several significant research-based manufacturers. Hamburg and the northern German region have a cluster of specialty and generic manufacturers. Berlin has a growing biotech scene connected to its research universities and the Charité hospital. Hesse is notable for its proximity to Frankfurt's logistics infrastructure and several major API manufacturers. Smaller but significant clusters exist in Saxony (Leipzig, Dresden) and Lower Saxony, benefiting from proximity to university research centres and historically established chemical industry sites.
Drug Classes and Product Segments
German pharmaceutical companies cover all major drug classes. Prescription (Rx) products account for the largest share of revenue; generics manufacturers such as Stada, ratiopharm (Teva) and Hexal produce chemically equivalent alternatives after patent expiry, significantly reducing costs for the healthcare system. Biologics and biosimilars are gaining ground rapidly: monoclonal antibodies, insulin analogues and recombinant growth factors require specialised biotech manufacturing facilities. OTC products (over-the-counter), i.e. medicines available without a prescription, represent a multi-billion-euro market served by companies such as Bayer Consumer Health, Stada and Klosterfrau. Homeopathic preparations, herbal medicines and dietary supplements form further regulated segments. Digitalisation is increasingly shaping the sector: Digital Health Applications (DiGA) have been reimbursable since 2020, and AI-assisted drug development is significantly shortening time-to-market.
What does a pharmaceutical company do?
Pharmaceutical companies develop, produce and distribute medicines. They cover the entire value chain from research and clinical trials through to market launch and distribution. In Germany, they are supervised by BfArM (the Federal Institute for Drugs and Medical Devices, comparable to the FDA or MHRA).
How are pharmaceutical companies regulated in Germany?
Pharmaceutical companies in Germany must hold a manufacturing authorisation under Section 13 of the AMG (German Medicinal Products Act). All authorised medicines require approval from either BfArM or the European Medicines Agency (EMA). Regular GMP (Good Manufacturing Practice) inspections ensure quality standards are maintained.
Where can I find contact details for pharmaceutical companies in Germany?
Industry associations such as vfa (Association of Research-Based Pharmaceutical Companies) and BPI (Federal Association of the German Pharmaceutical Industry) maintain member directories. Many companies also list their key contacts directly on their websites. Sanoliste provides a searchable directory of pharmaceutical companies in Germany sorted by federal state and city.
How many pharmaceutical companies are there in Germany?
Germany is home to more than 1,000 pharmaceutical companies employing approximately 130,000 people, according to vfa (the Association of Research-Based Pharmaceutical Companies) 2023 data. The sector includes multinational corporations, mid-sized specialty firms, generic manufacturers and biotech startups.
What is BfArM and what does it regulate?
BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte) is Germany's Federal Institute for Drugs and Medical Devices. It is a higher federal authority within the portfolio of the Federal Ministry of Health and is responsible for approving medicines for the German market, monitoring drug safety (pharmacovigilance), regulating narcotics and controlled substances, and overseeing medical devices in Germany. It is broadly comparable to the FDA in the United States or the MHRA in the United Kingdom.
What is the difference between BfArM approval and EMA approval?
Medicines in Germany can be approved through two main routes. BfArM grants national marketing authorisations valid in Germany, or decentralised and mutual recognition procedure approvals valid in multiple EU states. The EMA (European Medicines Agency) grants centralised marketing authorisations valid in all 27 EU member states simultaneously, typically used for innovative biologic medicines, oncology drugs and products for rare diseases.
What does GMP mean in the context of German pharmaceutical manufacturing?
GMP stands for Good Manufacturing Practice. In Germany and the EU, GMP compliance is a legal requirement for all pharmaceutical manufacturers under the AMG and the EU GMP Guidelines (EudraLex Volume 4). GMP covers all aspects of production including premises, equipment, personnel qualification, process validation, documentation and quality control. Compliance is verified by regular inspections from the competent state pharmaceutical supervisory authority.